Glioblastoma: How Optimizing Quality of Life Can Improve Treatment Outcomes
"A new study reveals the importance of QoL, cognitive function, and psychological well-being in glioblastoma patients undergoing standard treatments."
Glioblastoma (GBM) is a highly aggressive type of brain cancer that can significantly impact a patient's quality of life. Standard treatments, including radiotherapy (RT) and temozolomide (TMZ), aim to extend survival, but their impact on cognitive function, psychological well-being, and overall quality of life is an area of growing concern and active research.
A recent study published in the Annals of Oncology has shed light on the importance of addressing these factors in GBM patients. The research prospectively analyzed the quality of life (QoL), cognitive functions (CF), and psychological status (PSY) of GBM patients treated with RT and TMZ.
This article delves into the findings of this study, exploring how optimizing QoL, CF, and PSY can potentially improve treatment outcomes and enhance the overall well-being of individuals battling glioblastoma. Understanding these aspects is crucial for both patients and healthcare providers in navigating the complexities of GBM treatment.
Glioblastoma’s Burden
Glioblastoma multiforme is the most common and aggressive primary intracranial tumor, and one source reports a median survival of 14 months despite modern therapies. The Henry A. Swann, Jr. Foundation reports that more than 14,490 Americans were expected to receive a GBM diagnosis in 2023 and emphasizes high recurrence rates. The CBTRUS fact sheet states that glioblastoma most commonly occurs in the frontal, temporal, and parietal lobes; in national cancer registry data, approximately 2% had an IDH1/2 mutation and approximately 76% were IDH1/2 wildtype.
Standard Treatment Constraints
Upon initial diagnosis, standard treatment consists of maximal surgical resection, radiotherapy, and concomitant and adjuvant temozolomide chemotherapy. Reviews describe glioblastoma as rapidly growing, diffusely infiltrative, heterogeneous, and resistant to conventional therapies. Major therapeutic challenges include immune evasion, tumor repopulation by stem cells, and limited drug penetration across the blood-brain barrier. The 2021 World Health Organization classification restricted the diagnosis of glioblastoma to IDH-wildtype tumors.
Why Quality of Life Matters in Glioblastoma Treatment?
The aggressive nature of glioblastoma and the intensity of its treatment can lead to a range of challenges affecting a patient's daily life. Cognitive functions like memory, attention, and processing speed may be impaired, while psychological distress, including anxiety and depression, can further diminish overall well-being. These factors, in turn, can impact treatment adherence and effectiveness.
- EORTC QLQ-C30 and BN20: Used to assess the Quality of Life.
- MMSE: Used to evaluate Cognitive Functions.
- HADS Test: Used to evaluate Psychological Status.
Quality of Life in Recent Trials
In the randomized phase III EF-14 trial, health-related quality of life initially improved at 3 and 6 months for patients treated with tumor-treating fields plus temozolomide, with changes from baseline of 24% and 13%, respectively. The temozolomide-only group showed mild reductions of 7% and 17% at those time points. In the EPCOG trial, quality of life at month six favored early palliative care, but the difference was not statistically significant, with a mean difference of 4.1, a 95% confidence interval from −4.4 to 12.6, and P = .34.
When Aggressive Care Harms Quality of Life
Glioblastoma remains difficult to treat despite substantial advances in research. The available literature warns that medical professionals may unknowingly advocate aggressive interventions that adversely affect quality of life. A longitudinal study followed newly diagnosed patients receiving radiochemotherapy while continuously evaluating quality of life and cognitive functions. Another report describes glioblastoma as usually fatal, with poor overall survival of 10 to 14 months after treatment and a significant impact on quality of life.
Bevacizumab and Neurocognitive Outcomes
In the NRG/RTOG 0825 randomized trial, the median time to neurocognitive deterioration was 1.22 months for patients receiving placebo and 1.24 months for those receiving bevacizumab. The reported 95% confidence interval was 1.15 to 1.41 months for placebo and 1.12 to 1.81 months for bevacizumab. A 2026 network meta-analysis notes that targeted therapies have produced inconsistent results across randomized controlled trials. It also states that surgery combined with concurrent temozolomide chemoradiotherapy remains the current standard regimen but has limited efficacy.
The Future of Glioblastoma Care: A Holistic Approach
This study underscores the need for a holistic approach to glioblastoma care, one that integrates strategies to optimize QoL, CF, and PSY alongside standard treatments. By proactively addressing these factors, healthcare providers can potentially improve treatment adherence, enhance patient well-being, and ultimately improve outcomes for individuals battling this challenging disease. Further research is needed to explore specific interventions and strategies to effectively manage these aspects of glioblastoma care and to validate these finding in larger, more diverse populations.
Balancing Survival and Well-Being
A secondary analysis of a randomized clinical trial examined the association between tumor-treating fields plus temozolomide and both survival and health-related quality of life after completion of chemoradiotherapy. The analysis reflects the importance of evaluating treatment not only by survival outcomes but also by patients’ health-related quality of life. However, literature on glioblastoma management cautions that aggressive interventions can adversely affect quality of life. These findings support incorporating quality-of-life considerations into treatment decisions.
Systemic Challenges of Glioblastoma
Glioblastoma remains one of the most aggressive and lethal brain tumors in adults and continues to pose significant challenges to patient survival. The National Brain Tumor Society explains that these tumors affect the brain, which controls cognition, mood, behavior, personality, and the functions of the body. It also reports that the current standard of care can prolong life by only a few months on average while potentially reducing quality of life. These challenges make treatment effects on daily function an important part of the broader care context.
Patient and Caregiver Experience
Patient-reported outcomes in glioblastoma have been measured with the three-level EQ-5D, the EORTC QLQ-C30, and the brain cancer-specific QLQ-BN20. When patients could not complete the EQ-5D, caregiver proxy assessments were obtained. A 2024 real-world report described the clinical course of patients treated with a personalized neoantigen approach, while noting that prognosis remained poor despite new treatment options. In contrast, a 2025 patient account from MD Anderson illustrates that a person living with Grade 4 glioblastoma may still describe having a really good life.